Literature DB >> 8165194

Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina.

T Tuntland1, R J Ravasco, S al-Habet, J D Unadkat.   

Abstract

To determine if there is active efflux of zidovudine (ZDV) and 2',3'-dideoxyinosine (ddI) out of the cerebrospinal fluid (CSF), and if this efflux is saturable, we investigated the steady-state CSF/plasma concentration ratio of the two drugs when administered alone or in combination. Constant-rate infusions of ZDV, ddI or both were administered to seven macaques (Macaca nemestrina) through a chronic venous catheter for a minimum of 28 hr. Antipyrine, a marker of passive diffusion, was coinfused in all experiments. Blood (5 mL) and CSF samples (0.5-1 mL) were collected by venous and lumbar/thoracic punctures, respectively, at 24 and 28 hr after beginning the infusion. When ZDV and ddI were administered alone, the steady-state CSF/plasma concentration ratios were significantly different from unity (ZDV, 0.20 +/- 0.08; ddI, 0.09 +/- 0.04) and were independent of the plasma concentration (P > 0.05). In contrast, the CSF/plasma concentration ratio of antipyrine (0.82 +/- 0.19) was close but significantly smaller than unity (P > 0.05). The CSF/plasma concentration ratios after simultaneous administration of ZDV and ddI were not significantly different (P > 0.05) from those obtained after administration of the drugs alone. These results suggest that ZDV and ddI are actively transported out of the CSF; however, within the concentration range studied, this efflux is neither saturable nor mutually competitive. Concomitant administration of ZDV and ddI did not produce a systemic interaction in the animals, indicating that the pharmacokinetics of either drug is unaffected by the presence of the other.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8165194     DOI: 10.1023/a:1018928013044

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

1.  Clinical response to dideoxyinosine in patients with HIV infection resistant to zidovudine.

Authors:  M C Bach
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

2.  Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier.

Authors:  T Terasaki; W M Pardridge
Journal:  J Infect Dis       Date:  1988-09       Impact factor: 5.226

3.  Probenecid-induced accumulation of 5-hydroxyindoleacetic acid and homovanillic acid in rat brain.

Authors:  B M Emanuelsson; L Paalzow; M Sunzel
Journal:  J Pharm Pharmacol       Date:  1987-09       Impact factor: 3.765

4.  Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

Authors:  G Ahluwalia; D A Cooney; H Mitsuya; A Fridland; K P Flora; Z Hao; M Dalal; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-11-15       Impact factor: 5.858

5.  Fluorescence polarization immunoassay for zidovudine.

Authors:  G G Granich; M R Eveland; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Renal secretion of 3'-azido-3'-deoxythymidine by the rat.

Authors:  J Y Chatton; M Odone; K Besseghir; F Roch-Ramel
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

7.  Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit.

Authors:  M A Hedaya; R J Sawchuk
Journal:  J Pharm Sci       Date:  1989-09       Impact factor: 3.534

8.  Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate.

Authors:  A Lopez-Anaya; J D Unadkat; L A Schumann; A L Smith
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

9.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Authors:  J O Kahn; S W Lagakos; D D Richman; A Cross; C Pettinelli; S H Liou; M Brown; P A Volberding; C S Crumpacker; G Beall
Journal:  N Engl J Med       Date:  1992-08-27       Impact factor: 91.245

10.  Effect of age on distribution of zidovudine (azidothymidine) into the cerebrospinal fluid of Macaca nemestrina.

Authors:  A Lopez-Anaya; J D Unadkat; D F Calkins; A L Smith
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

View more
  7 in total

Review 1.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

2.  Evaluation of a brain-targeting zidovudine chemical delivery system in dogs.

Authors:  M E Brewster; W R Anderson; A I Webb; L M Pablo; D Meinsma; D Moreno; H Derendorf; N Bodor; E Pop
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

3.  Zidovudine does not affect transplacental transfer or systemic clearance of stavudine (2',3'-didehydro-3'-deoxythymidine) in the pigtailed macaque (Macaca nemestrina).

Authors:  A Odinecs; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Effect of zidovudine on transplacental pharmacokinetics of ddI in the pigtailed macaque (Macaca nemestrina).

Authors:  C M Pereira; C Nosbisch; W L Baughman; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

5.  Pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in the neonatal macaque (Macaca nemestrina).

Authors:  R D Keller; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

6.  Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex.

Authors:  D M Burger; C L Kraayeveld; P L Meenhorst; J W Mulder; R M Hoetelmans; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1995-11-24

Review 7.  Drug interactions at the blood-brain barrier: fact or fantasy?

Authors:  Sara Eyal; Peng Hsiao; Jashvant D Unadkat
Journal:  Pharmacol Ther       Date:  2009-04-22       Impact factor: 13.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.